ESMO Congress 2017
01 Sep 2017
Next Friday marks the beginning of the ESMO Congress 2017, where MRC Clinical Trials Unit at UCL will be presenting results from prostate and ovarian cancer trials.
The ESMO Congress brings together a large number of oncology professionals from across Europe. It will take place from Friday 8 September to Tuesday 12 September, in Madrid, Spain.
Details of the MRC CTU at UCL presentations taking place at ESMO 2017 are shown below.
|
Day |
Session (local time) |
Session Type |
Title |
Author(s) |
Location |
|
08 September 2017 |
14:00 - 14:12 |
Paper Session: Genitourinary tumours, prostate |
Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE |
M. Sydes et al. |
Sevilla Auditorium |
|
08 September 2017 |
14:00 - 15:30 |
Primary and secondary prevention of cancer: Where do we stand |
Aspirin for prevention and adjuvant treatment of cancer |
R. Langley |
Cartagena Auditorium |
|
08 September 2017 |
16:00 - 16:12 |
Paper Session: Gynaecological Cancers |
ICON8: A GCIG Phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment: Results of Primary Progression- Free Survival (PFS) analysis |
A. Clamp et al. |
Cordoba Auditorium |
|
09 September 2017 |
13:15 - 14:15 |
Poster Display Session |
ICON7: ovarian cancer, platinum second-line chemotherapy and overall survival |
A. Cook et al. |
Hall 8 |
|
10 September 2017 |
09:15 - 10:30 |
Poster Discussion Session: Genitourinary tumours, prostate |
What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis |
C. Vale et al. |
Bilbao Auditorium |
|
10 September 2017 |
09:15 - 10:30 |
Poster Discussion Session: Genitourinary tumours, prostate |
Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE |
N. James et al. |
Bilbao Auditorium |
For further information see the following study pages: STAMPEDE, ICON8, STOPCaP and ICON7.